Recon: FDA rejects Aquestive’s allergy therapy over packaging concerns; Novo’s CagriSema tops Wegovy in Phase 3 diabetes study

ReconReconBiotechnologyEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States